Loading
A 2015 Baylor study of 198 triple-negative tumours that found four stable subtypes, luminal androgen receptor, mesenchymal, basal-like immune-suppressed and basal-like immune-activated, with the immune-activated group faring best and the immune-suppressed worst.
Burstein, Tsimelzon, Poage, Covington and colleagues profiled RNA and DNA in 198 triple-negative tumours (oestrogen receptor negativity defined as Allred score 2 or less, more than 50 percent cellularity; discovery 84, validation 114) collected at Baylor College of Medicine, with an external set of seven public studies for confirmation. Four subtypes were identified and confirmed: luminal androgen receptor (LAR), mesenchymal (MES), basal-like immunosuppressed (BLIS) and basal-like immune-activated (BLIA). Prognosis was worst for BLIS and best for BLIA for both disease-free survival (p=0.042 and 0.041) and disease-specific survival (p=0.039 and 0.029). Copy number analysis separated LAR from the other three and suggested amplification drives expression in some cases (FGFR2 in BLIS). Candidate subtype-specific targets were androgen receptor and MUC1 (LAR), PDGF receptor A and c-Kit (MES), VTCN1 (BLIS) and Stat molecules and cytokines (BLIA).
Independently arrived at the same partition as the refined Lehmann scheme and added the insight that immune activation within basal-like tumours separates good from poor prognosis, the biology immunotherapy would exploit three years later.
Shares Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, Androgen receptor, Tumour heterogeneity and clonal evolution, RNA sequencing & expression profiling and the tag tnbc-evidence.
Shares Clinical Cancer Research, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares RNA sequencing & expression profiling, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Tumour heterogeneity and clonal evolution, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.